Polypoidal Choroidal Vasculopathy Clinical Trial
This is a prospective, comparative control analysis. The investigators want to evaluate the aqueous humor levels of vascular endothelial growth factor in polypoidal choroidal vasculopathy and the effect of photodynamic therapy and combination treatment of photodynamic therapy and Lucentis (Ranibizumab)on the level of vascular endothelial growth factor.
To compare the effect of combination therapy of intravitreal injection of Lucentis™ and photodynamic therapy versus only photodynamic therapy on aqueous humor vascular endothelial growth factor level in polypoidal choroidal vasculopathy patients to establish the vascular endothelial growth factor expression after photodynamic therapy and the direct effect of Lucentis™ on this increased vascular endothelial growth factor level. Additionally the investigators want to examine the vascular endothelial growth factor , tumor necrosis factor alpha, interleukin-2, interleukin-6 and interleukin-8 level of aqueous humor in symptomatic, active polypoidal choroidal vasculopathy patients. ;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Active, not recruiting |
NCT01950741 -
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Completed |
NCT01469156 -
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT02597855 -
Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography
|
N/A | |
Completed |
NCT02495181 -
Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Active, not recruiting |
NCT02976194 -
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Recruiting |
NCT01248117 -
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01884597 -
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04707027 -
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
|
N/A | |
Recruiting |
NCT02141308 -
OCT in Rare Chorioretinal Diseases
|
||
Completed |
NCT01871376 -
Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation
|
Phase 4 | |
Completed |
NCT00470977 -
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT00383812 -
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
|
N/A | |
Completed |
NCT00837330 -
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
|
Phase 1/Phase 2 | |
Completed |
NCT05229237 -
Conbercept for Polypoidal Choroidal Vasculopathy(START Study)
|
||
Not yet recruiting |
NCT04380974 -
Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Recruiting |
NCT02815176 -
Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers
|
N/A | |
Active, not recruiting |
NCT00344617 -
Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy
|
Phase 3 | |
Recruiting |
NCT03929731 -
Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
|
||
Completed |
NCT01023295 -
Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
|
Phase 2 |